Abstract
Chronic hepatitis B virus (HBV) infection affects over 350 million people worldwide and over 1 million die annually of HBV-related chronic liver disease. The prolonged immunologic response to HBV infection leads to the development of cirrhosis, liver failure, or hepatocellular carcinoma (HCC) in up to 40% of patients. The implementation of mass immunization programs has dramatically decreased the incidence of HBV infection among infants, children, and adolescents in many countries, but there remains a large number who were infected with HBV before such programs. A variety of host, viral, and external factors influence HBV disease progression and the risk of chronic infection. Six drugs are currently FDA-approved for the treatment of chronic HBV infection. While novel antiviral drugs have improved the management of cirrhosis, strategies to prevent and treat HCC remain inadequate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
